Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Liabilities (2019 - 2025)

Legend Biotech filings provide 7 years of Total Liabilities readings, the most recent being $731.6 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 16.2% to $731.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $731.6 million, a 16.2% increase, with the full-year FY2025 number at $731.6 million, up 16.2% from a year prior.
  • Total Liabilities hit $731.6 million in Q4 2025 for Legend Biotech, up from $701.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $535.2 billion in Q2 2021 to a low of $353.5 million in Q4 2021.
  • Median Total Liabilities over the past 5 years was $606.5 million (2022), compared with a mean of $53.0 billion.
  • Biggest five-year swings in Total Liabilities: skyrocketed 184.36% in 2021 and later plummeted 99.85% in 2022.
  • Legend Biotech's Total Liabilities stood at $353.5 million in 2021, then surged by 65.95% to $586.7 million in 2022, then grew by 1.8% to $597.2 million in 2023, then rose by 5.42% to $629.6 million in 2024, then grew by 16.2% to $731.6 million in 2025.
  • The last three reported values for Total Liabilities were $731.6 million (Q4 2025), $701.7 million (Q3 2025), and $654.4 million (Q2 2025) per Business Quant data.